March 2012

Click to download the PDF to view the full issue

March 1, 2012/by Administrator

Share this entry

https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 Administrator https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Administrator2012-03-01 12:12:312015-03-15 12:16:05March 2012

Recent

Illumina expands board after fight with IcahnJune 2, 2023 - 11:02 am
Pfizer’s antibiotic combo clears Phase III, shows promise...June 2, 2023 - 10:29 am
Reuters HealthNovartis drug cuts recurrence risk by 25% in early-stage...June 2, 2023 - 8:06 am
BioNTech’s OncoC4 partnership off to good start with...June 2, 2023 - 7:51 am

Popular

Illumina expands board after fight with IcahnJune 2, 2023 - 11:02 am
M&A, Partnerships And CollaborationsJanuary 1, 2011 - 1:48 pm
OTC Review And OutlookMarch 9, 2011 - 4:17 pm
Global Contract Manufacturing Companies: Pharmaceutical...November 11, 2011 - 3:31 pm

Tags

AbbVie acquisition Alzheimer's disease artificial intelligence AstraZeneca Biogen BioNTech Bristol-Myers Squibb cancer China clinical trial clinical trials Covid-19 COVID-19 pandemic COVID-19 vaccine COVID-19 vaccines Drug development Eli Lilly European Union FDA gene therapy GSK healthcare communications healthcare marketing Johnson & Johnson leadership Merck Merck & Co. Moderna monkeypox Novartis Novo Nordisk Oncology pandemic patient safety people on the move Pfizer rare disease regulatory approval Roche Sanofi U.S. Centers for Disease Control and Prevention (CDC) U.S. Food and Drug Administration (FDA) United States World Health Organization

Fenruary 2012 April 2012

Scroll to top